Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796377 | 0.93 | NT5E (0.39) | LMNANT5E | |
| SCHEMBL2796378 | 0.93 | NT5E (0.39) | LMNANT5E | |
| SCHEMBL25413683 | 0.90 | NT5E (0.36) | LMNAKMT2APOLBNT5EMCHR1 | |
| SCHEMBL25413680 | 0.90 | NT5E (0.36) | LMNAKMT2APOLBNT5EMCHR1 | |
| SCHEMBL25414613 | 0.87 | PDPK1 (0.34) | LMNAKMT2APOLBNT5EPDPK1 | |
| SCHEMBL25414267 | 0.87 | MCHR1 (0.39) | MCHR1SSTR3SSTR5 | |
| SCHEMBL2798123 | 0.82 | TACR2 (0.39) | LMNAPOLBNT5EMCHR1L3MBTL1 | |
| SCHEMBL2798128 | 0.82 | TACR2 (0.39) | LMNAPOLBNT5EMCHR1L3MBTL1 | |
| SCHEMBL13231369 | 0.82 | TACR2 (0.39) | LMNAPOLBNT5EMCHR1L3MBTL1 | |
| SCHEMBL7141594 | 0.82 | LMNA (0.31) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4245763-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002425-A1 | NOVEL AMINOALKYL GLUCOSAMINIDE 4-PHOSPHATE DERIVATIVE | TLR4, TLR5, TLR9 | LMNA 4111/4885KMT2A 1667/4885POLB 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.